Reported 3 days ago
Boston Scientific Corporation (BSX), with a market cap of $144.2 billion, specializes in innovative medical devices across various specialties. The company is set to report its Q3 2025 earnings on October 22, with analysts predicting an adjusted EPS of $0.71, a 12.7% increase year-over-year. Despite a 14.5% rise in shares over the past year, BSX has underperformed compared to the S&P 500. However, strong demand for cardiovascular devices and a recent earnings beat contributed to a bullish consensus among analysts, who anticipate a 30.5% upside from the current stock levels.
Source: YAHOO